| Literature DB >> 34139439 |
Samantha C Pendleton1, Luke T Slater2, Andreas Karwath3, Rose M Gilbert4, Nicola Davis5, Konrad Pesudovs6, Xiaoxuan Liu7, Alastair K Denniston8, Georgios V Gkoutos3, Tasanee Braithwaite9.
Abstract
BACKGROUND: Unstructured text created by patients represents a rich, but relatively inaccessible resource for advancing patient-centred care. This study aimed to develop an ontology for ocular immune-mediated inflammatory diseases (OcIMIDo), as a tool to facilitate data extraction and analysis, illustrating its application to online patient support forum data.Entities:
Keywords: Inflammation; Ontology; Patient voice; Sentiment; Uveitis
Mesh:
Year: 2021 PMID: 34139439 PMCID: PMC8404035 DOI: 10.1016/j.compbiomed.2021.104542
Source DB: PubMed Journal: Comput Biol Med ISSN: 0010-4825 Impact factor: 4.589
Fig. 1Graphical representation of the ocular immune-mediated inflammatory diseases ontology, with a close-up of systemic, non-infectious disease associations. Each node is a class (e.g. “multiple sclerosis”) and each edge is a relationship, with dotted lines defining “subclass of” and solid lines defining constructed relationships, labelled with boxes (e.g. “investigated by”).
Examples of constructed relationship types contained in OcIMIDo.
| Relationship | Count | Cross-reference | Example | Notes about meaning |
|---|---|---|---|---|
| adjacent to | 62 | RO:0002220 | choroid is adjacent to the sclera | Anatomical descriptor |
| part of has part | 104 | BFO:0000050 | choroid is part of the uvea | Anatomical descriptor (where the inverse is always true) |
| characterised by | 20 | SCDO:0000662 | sarcoidosis is characterised by granulomatous histopathology | Disease definition (unidirectional) |
| investigated by investigation for | 84 | None applicable | Reiter's investigated by HLA-B27 | Investigations included in Royal College of Ophthalmology Consensus document [24] (inverse is always true) |
| is a | 657 | None applicable | oral is a route of administration | Defines what something is (unidirectional as it is defining subclass relations) |
| occurs in | 57 | BFO:0000066 | retinitis occurs in the retina | Descriptor of pathology in relation to anatomy or life-course stage (unidirectional) |
| treatment of | 16 | RO:0002606 | (unidirectional) |
Illustration of the frequency count of a selection of some of the 661 OcIMIDo class items in the posts from the two patient fora.
*OR from Multivariable logistic regression model, also adjusted for first post (versus replies to a thread). Otherwise, odds ratios are for single variable analysis.
KEY: OV oliviasvision.org; UVE uveitis.org.
| OcIMIDo ontology class | All posts (n = 9031) | Most negative + positive 25th posts, Odds of post expressing negative sentiment OR (95% CI), p value | |||
|---|---|---|---|---|---|
| OV forum % (n) | UVE forum % (n) | Chi2 p value | TextBlob (n = 4480) | VADER (n = 4557) | |
| Scleritis | 0.1 (2) | 2.7 (184) | p < 0.001 | 1.9 (1.2–3.2), p = 0.007 | 1.3 (0.9–1.9), p = 0.207 |
| Anterior uveitis | 5.7 (124) | 8.4 (577) | p < 0.001 | 2.3 (1.7–3.1), p < 0.001* | 1.3 (1.0–1.5), p = 0.027 |
| Intermediate uveitis | 1.8 (38) | 5.8 (397) | p < 0.001 | 1.5 (1.0–2.1), p = 0.041 | 0.8 (0.6–1.1), p = 0.145 |
| Macular oedema | 1.4 (31) | 2.1 (144) | p = 0.046 | 1.3 (0.7–2.4), p = 0.389 | 0.5 (0.3–0.7), p = 0.001 |
| Posterior uveitis | 0.9 (20) | 2.6 (179) | p < 0.001 | 1.4 (0.8–2.3), p = 0.263 | 0.5 (0.3–0.7), p < 0.001 |
| Panuveitis | 1.5 (32) | 1.7 (113) | p = 0.565 | 1.8 (1.0–3.5), p = 0.070 | 0.6 (0.4–1.0), p = 0.036 |
| Optic neuritis | 0 (0) | 1.0 (70) | p < 0.001 | 1.1 (0.5–2.2), p = 0.895 | 0.9 (0.5–1.7), p = 0.829 |
| Ankylosing spondylitis | 0.7 (16) | 1.6 (109) | p = 0.003 | 1.3 (0.6–2.5), p = 0.515 | 0.8 (0.5–1.3), p = 0.370 |
| Behcet's disease | 0.3 (7) | 1.3 (92) | p < 0.001 | 0.7 (0.4–1.4), p = 0.290 | 0.7 (0.4–1.2), p = 0.214 |
| Inflammatory bowel disease | 2.2 (152) | 0.5 (11) | p < 0.001 | 1.3 (0.7–2.3), p = 0.351 | 1.0 (0.6–1.4), p = 0.844 |
| Birdshot | 0.60 (13) | 1.01 (69) | p = 0.080 | 0.8 (0.3–1.7), p = 0.516 | 0.4 (0.2–0.7), p = 0.001 |
| Juvenile idiopathic arthritis | 4.5 (97) | 1.5 (105) | p < 0.001 | 1.7 (1.0–3.0), p = 0.052* | 0.6 (0.4–0.9), p = 0.017 |
| Multiple sclerosis | 0.4 (8) | 1.7 (119) | p < 0.001 | 2.1 (1.0–4.2), p = 0.049 | 1.0 (0.6–1.5), p = 0.842 |
| Psoriasis | 0.3 (7) | 1.7 (113) | p < 0.001 | 0.9 (0.5–1.9), p = 0.813 | 1.1 (0.7–1.8), p = 0.688 |
| Rheumatoid arthritis | 0.7 (16) | 1.1 (78) | p = 0.107 | 2.8 (1.1–7.2), p = 0.029* | 1.2 (0.7–2.1), p = 0.453 |
| Cat scratch disease | 1.0 (1) | 0.2 (8) | p = 0.356 | 8.2 (1.0–67.5), p = 0.050* | 1.2 (0.5–2.7), p = 0.702 |
| Sarcoidosis | 0.1 (1) | 0.3 (19) | p = 0.046 | 2.0 (0.4–10.7), p = 0.437 | 0.5 (0.1–1.6), p = 0.244 |
| Cataract | 10.0(218) | 7.1 (483) | p < 0.001 | 1.6 (1.2–2.2), p = 0.003* | 1.5 (1.1–2.0), p = 0.018 |
| Glaucoma | 3.72 (81) | 5.3 (363) | p = 0.003 | 1.8 (1.3–2.5), p = 0.001 | 1.3 (0.9–1.8), p = 0.231 |
| Epiretinal membrane | 0.28 (6) | 0.93 (65) | p = 0.002 | 2.7 (0.9–8.5), p = 0.089 | 2.4 (0.7–8.0), p = 0.145 |
| Ocular Hypertension | 1.19 (26) | 0.53 (36) | p = 0.001 | 2.5 (1.0–6.4), p = 0.063 | 0.2 (0.1–0.5), p = 0.238 |
| Retinal detachment | 0.6 (13) | 0.47 (32) | p = 0.451 | 1.0 (0.3–3.4), p = 0.975 | 0.2 (0.1–0.5), p = 0.001 |
| Oral prednisolone | 6.2 (135) | 4.8 (329) | p = 0.010 | 2.2 (1.5–3.4), p < 0.001* | 1.3 (1.0–1.7), p = 0.040 |
| Intravitreal triamcinolone | 0.09 (2) | 0.64 (44) | p = 0.002 | 7.9 (1.0–64.4), p = 0.055* | 1.1 (0.5–2.4), p = 0.742 |
| Topical steroid | 6.0 (130) | 3.3 (224) | p < 0.001 | 2.0 (1.3–3.1), p = 0.002* | 1.5 (1.1–2.0), p = 0.014 |
| Methotrexate | 15.3 (333) | 13.6 (937) | p = 0.056 | 1.5 (1.2–1.9), p < 0.001* | 0.8 (0.7–1.0), p = 0.003 |
| Mycophenolate mofetil | 1.88 (41) | 5.16 (356) | p < 0.001 | 1.7 (1.2–2.5), p = 0.004 | 0.6 (0.4–0.7), p < 0.001 |
| Adalimumab | 7.22 (495) | 10.02 (218) | p < 0.001 | 1.5 (1.2–1.9), p = 0.001 | 0.9 (0.7–1.0), p = 0.131 |
| Bevacizumab | 0.23 (5) | 1.27 (87) | p < 0.001 | 1.1 (0.5–2.3), p = 0.888 | 0.2 (0.1–0.4), p < 0.001 |
| Rituximab | 0.09 (2) | 1.15 (79) | p < 0.001 | 0.7 (0.4–1.3), p = 0.247 | 0.2 (0.1–0.5), p < 0.001 |
| Infliximab | 3.81 (83) | 5.25 (360) | p = 0.007 | 1.3 (0.9–1.7), p = 0.118 | 0.7 (0.6–0.9), p = 0.019 |
| TOTAL | 100 (2176) | 100 (6855) | |||
Fig. 2Box plots illustrating spread of natural language sentiment scores with TextBlob for a range of clinical phenotypes, complications, systemic non-infectious diseases, and systemic treatments, combining data from Olivia's Vision and The Ocular Immunology and Uveitis Foundation fora. The scores for each class (including synonyms) ranged from −1.00 (most negative language) to +1.00 (most positive language).